Jasper Therapeutics News and Activities

View the org chart displaying its 19 main executives

Most searched biographies at Jasper Therapeutics

• Jeet Mahal, President and Chief Executive Officer and Director
• Judith Shizuru, Director
• Thomas Wiggans, Executive Chairman of the Board

Popular executive movements at Jasper Therapeutics

• Chris Nolet, Director, has left the company  (posted on May 22 2026).
• Ronald Martell, Chief Executive Officer and Director, has left the company  (posted on January 8 2026).
• Jeet Mahal, who was Chief Operating Officer, is promoted to President and Chief Executive Officer and Director  (posted on January 8 2026).

Create your alert
to follow the executive moves at Jasper Therapeutics.

Jasper Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Jasper Therapeutics

• News Releases | Jasper Therapeutics, Inc
• News Releases | Jasper Therapeutics, Inc
• Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
• Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
• Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
• Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
• Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
• Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
• Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
• Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
• View more press releases Close

Social media about Jasper Therapeutics

• Jasper Therapeutics on Wikipedia, Google News & Yahoo Finance
• Jasper Therapeutics on LinkedIn, X (Twitter) & YouTube